To determine whether samfenet is effective in the HER2-positive ovarian cancer preclinical model, HER2 expression in various ovarian cancer cell lines, including SKOV3, A2780, OVCAR3, SNU-119, and SNU-251, was assessed. Here, ERBB2 is linked to ovarian carcinoma.